Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Alebund Pharma Raises $54.5 Million for Renal Disease Therapies

publication date: Sep 14, 2021

Alebund Pharma, a Shanghai company focused on renal diseases, closed a $54.5 million Series B+ financing round. Four months ago, the company completed a $60 million B round. Alebund will use the proceeds to advance its clinical programs, build a manufacturing facility, research its pre-clinical assets and hire additional staff. Its lead program is a treatment for hyperphosphatemia, currently in a Phase II clinical trial. The B+ round was led by 3H Health Investment, Loyal Valley Capital and Morningside Ventures. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
The Ritz-Carlton Shanghai Pudong
March 23-25, 2021